SAM
EWTX icon

SEB Asset Management’s Edgewise Therapeutics EWTX Stock Holding History

SEB Asset Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.88M Sell
194,063
-12,449
-6% -$429K 0.03% 378
2026
Q1 		$6.51M Buy
+206,512
New +$5.96M 0.03% 408

Other funds holding EWTX

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

SEB Asset Management's EWTX Position: Q2 2026 in Review

SEB Asset Management reduced its Edgewise Therapeutics (EWTX) stake by 6% in Q2 2026, selling an estimated $429K and leaving 194,063 shares worth $7.88M. The position accounts for 0.03% of the portfolio, ranked #378.

SEB Asset Management first reported a position in EWTX in Q1 2026 and has held it in 2 quarters since. 205 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • SEB Asset Management held 194,063 shares of Edgewise Therapeutics worth $7.88M as of Q2 2026.
  • SEB Asset Management sold 12,449 Edgewise Therapeutics shares in Q2 2026, an estimated $429K.
  • Edgewise Therapeutics made up 0.03% of SEB Asset Management's portfolio in Q2 2026, its #378 holding.
  • SEB Asset Management first reported a position in Edgewise Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 205 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on SEB Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.